ATE320247T1 - Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion - Google Patents

Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion

Info

Publication number
ATE320247T1
ATE320247T1 AT99964644T AT99964644T ATE320247T1 AT E320247 T1 ATE320247 T1 AT E320247T1 AT 99964644 T AT99964644 T AT 99964644T AT 99964644 T AT99964644 T AT 99964644T AT E320247 T1 ATE320247 T1 AT E320247T1
Authority
AT
Austria
Prior art keywords
sexual dysfunction
pde5 inhibitors
cgmp pde5
inhalation treatment
pyrimidin
Prior art date
Application number
AT99964644T
Other languages
English (en)
Inventor
Reto Naef
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE320247T1 publication Critical patent/ATE320247T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dispersion Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT99964644T 1998-12-22 1999-12-21 Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion ATE320247T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828340.1A GB9828340D0 (en) 1998-12-22 1998-12-22 Organic compounds

Publications (1)

Publication Number Publication Date
ATE320247T1 true ATE320247T1 (de) 2006-04-15

Family

ID=10844812

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99964644T ATE320247T1 (de) 1998-12-22 1999-12-21 Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion

Country Status (11)

Country Link
US (3) US20010055570A1 (de)
EP (1) EP1140044B1 (de)
JP (1) JP2002532542A (de)
AT (1) ATE320247T1 (de)
AU (1) AU3041900A (de)
CA (1) CA2355368A1 (de)
DE (1) DE69930416T2 (de)
ES (1) ES2260952T3 (de)
GB (1) GB9828340D0 (de)
PT (1) PT1140044E (de)
WO (1) WO2000037061A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6919337B2 (en) 2000-04-07 2005-07-19 Novartis, Ag 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US7019136B2 (en) 2000-04-07 2006-03-28 Novartis, Ag 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
KR20080015594A (ko) * 2006-08-16 2008-02-20 주식회사종근당 포스포디에스테라제 저해제로서 유용한 퀴나졸린 유도체 및그 제조방법
CA2663436A1 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US20110225023A1 (en) * 2010-03-09 2011-09-15 Target Brands, Inc. Prioritized Product Distribution
EP2526926A1 (de) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9315017D0 (en) * 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5728705A (en) * 1993-10-04 1998-03-17 The Trustees Of Columbia University In The City Of New York Method of inducing vasorelaxation to treat pulmonary hypertension
DE4420708A1 (de) * 1994-06-14 1995-12-21 Euro Celtique Sa Entzündungshemmende Zusammensetzung zur Inhalation
GB9423910D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
JPH11501926A (ja) * 1995-03-10 1999-02-16 サノフィ ファーマシューティカルズ インコーポレイティド ６−アリールピラゾロ［３，４−ｄ］ピリミジン−４−オン、並びにその組成物及び使用法
PT828728E (pt) * 1995-05-18 2003-06-30 Altana Pharma Ag Di-hidrobenzofuranos de fenilo
ATE230404T1 (de) * 1995-05-18 2003-01-15 Altana Pharma Ag Cyclohexyldihydrobenzofurane
DE19541264A1 (de) * 1995-11-06 1997-05-07 Bayer Ag Purin-6-on-derivate
EE03523B1 (et) * 1996-01-31 2001-10-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
KR20000010919A (ko) * 1996-05-31 2000-02-25 모치다 에이 Cgmp­pde 저해작용이 있는 피리도카르바졸 유도체
JP2001503443A (ja) * 1996-11-11 2001-03-13 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 新規イミダゾ―及びオキサゾロピリジン
JP2001504462A (ja) * 1996-11-12 2001-04-03 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング ホスホジエステラーゼ阻害剤としての（２，３―ジヒドロベンゾフラニル）―チアゾール
IL132993A0 (en) * 1997-05-29 2001-03-19 Mochida Pharm Co Ltd Therapeutic agent for erection failure
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
NZ509328A (en) * 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
DE69916627T2 (de) * 1998-09-04 2005-07-28 Ortho-Mcneil Pharmaceutical, Inc. 5-heterozyklyl-pyrazolo[4,3-d]pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen

Also Published As

Publication number Publication date
CA2355368A1 (en) 2000-06-29
DE69930416T2 (de) 2006-11-02
EP1140044A2 (de) 2001-10-10
ES2260952T3 (es) 2006-11-01
US20070197560A1 (en) 2007-08-23
PT1140044E (pt) 2006-07-31
DE69930416D1 (de) 2006-05-11
US20040214831A1 (en) 2004-10-28
AU3041900A (en) 2000-07-12
US20010055570A1 (en) 2001-12-27
WO2000037061A2 (en) 2000-06-29
JP2002532542A (ja) 2002-10-02
EP1140044B1 (de) 2006-03-15
GB9828340D0 (en) 1999-02-17
WO2000037061A3 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
HRP20070534T3 (en) Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
CO5271711A1 (es) Una composicion que comprende sildenafil o 3-etil-5-[5-(4-etil-piperazina-1-sulfonil)-2-propoxi-fenil]-2-piridinh-2-ilmetil-2.6-dihidropirazolo[4,3-d]pirimidin-7-ona y gabapentina o pregabalina para el tratamiento de la neuropatia diabetica
ATE362474T1 (de) Pyrazolo(1,5-a)pyrimidine als hemmstoffe cyclin- abhängiger kinasen
ATE469903T1 (de) Zur behandlung von krebserkrankungen geeignete pyrazolopyrimidine
DE69930416D1 (de) Cgmp pde5 inhibitoren zur inhalationsbehandlung von sexueller dysfunktion
NZ590922A (en) Piperidine derivatives as jak3 inhibitors
HRP20150987T1 (hr) UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
WO2004009597A3 (en) Pyrazolopyrimidines as protein kinase inhibitors
BR9609011A (pt) Composto
RU2008131792A (ru) Комбинация избирательного ингибитора обратного захвата норадреналина и ингибитора pdev
WO2008058126A3 (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
ZA200802998B (en) Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases
IS6288A (is) 5-(2-setnin-5-heterósýklýlsúlfónýlpýrid-3-ýl)díhýdrópýrazóló[4,3-d]pýrimidín-7-ón sem fosfódíesterasa latar
DK1699795T3 (da) Substituerede 8'-pyri(mi)dinyldihydrospiro[cycloalkylamin]-pyrimido[1,2-a]pyrimidin-6-onderivater
DK1430057T3 (da) Substituerede 2-pyridinyl-6,7,8, 9-tetrahydropyrimido [1,2-a] pyrimidin-4-on- og 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)onderivater
EP1383769A4 (de) Als cyclinabhängige kinase-inhibitoren geeignete 6-substituierte pyrazolo-3,4-d]pyrimidin-4-one
WO2004106339A3 (en) 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
EP1085871A4 (de) Quinazolinonehemmendern von cgmp phosphodiesterase
ATE309246T1 (de) 1-(alkyl), 1-(heteroaryl)alkyl und 1-(aryl)alkyl)-7-(pyrimidin-4-yl)-imidazo(1,2-a pyrimidin-5(h)- one derivate
SI4259632T1 (sl) Derivati N-(imidazo(1,2-b)piridazin-3-il)-1-cikloheksil-2H-indazol-5- karboksamida in N-(pirazolo(1,5-a)pirimidin-3-il)-1-cikloheksil-2H- indazol-5-karboksamida kot zaviralci IRAK4 za zdravljenje astme
AU2977084A (en) Pyrazolo-(1,5-a) pyrimidin derivatives
DK1678182T3 (da) Fremgangsmåde til fremstilling af substituerede 5-amino-pyrazolo[4,3-E]-1,2,4-triazolo-[1,5-C]pyrimidiner
ATE377599T1 (de) Verfahren zur herstellung von substituierten 5- aminopyrazolo(4,3-e)-1,2,4-triazolo(1,5- c)pyrimidinen
MX2024007517A (es) Formas solidas de compuestos de pirazolo[3,4-d]pirimidina.
DE69514270D1 (de) 5-ALKOXY[1,2,4]TRIAZOLO[1,5-c]PYRIMDIN-2(3H)-THIONVERBINDUNGEN UND IHRE VERWENDUNG ZUR HERSTELLUNG VON 2,2'-DITHIOBIS(5-ALKOXY[1,2,4]TRIAZOLO [1,5-c]PYRIMIDIN) UND 2-CHLOROSULFONYL-5-ALKOXY[1,2,4]TRIAZOLO[1,5-c] PYRIMIDINVERBINDUNGEN

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140044

Country of ref document: EP

REN Ceased due to non-payment of the annual fee